Evidence map›Paper›PMID 36324497›Full record

ArticleRSC medicinal chemistry2022

Shoko Shinya, Ritsuko Katahira, Kyoko Furuita, Toshihiko Sugiki, Young-Ho Lee, Yoshikazu Hattori, Kohei Takeshita, Atsushi Nakagawa, Aoi Kokago, Ken-Ichi Akagi and 6 more

Abstract read
In one paragraph

Article in RSC medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Perspectives on Applications ofMolecules (Basel, Switzerland) · 2024
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Shoko ShinyaInstitute for Protein Research, Osaka University 3-2 Yamadaoka Suita Osaka 565-0871 Japan.
Ritsuko KatahiraInstitute for Protein Research, Osaka University 3-2 Yamadaoka Suita Osaka 565-0871 Japan.
Kyoko FuruitaInstitute for Protein Research, Osaka University 3-2 Yamadaoka Suita Osaka 565-0871 Japan.
Toshihiko SugikiInstitute for Protein Research, Osaka University 3-2 Yamadaoka Suita Osaka 565-0871 Japan.
Young-Ho LeeInstitute for Protein Research, Osaka University 3-2 Yamadaoka Suita Osaka 565-0871 Japan.ORCID https://orcid.org/0000-0002-8441-5814
Yoshikazu HattoriInstitute for Protein Research, Osaka University 3-2 Yamadaoka Suita Osaka 565-0871 Japan.
Kohei TakeshitaInstitute for Protein Research, Osaka University 3-2 Yamadaoka Suita Osaka 565-0871 Japan.
Atsushi NakagawaInstitute for Protein Research, Osaka University 3-2 Yamadaoka Suita Osaka 565-0871 Japan.ORCID https://orcid.org/0000-0002-1700-7861
Aoi KokagoGraduate School of Engineering Science, Yokohama National University Tokiwadai 79-5, Hodogaya-ku Yokohama 2408501 Japan kojima-chojiro-xk@ynu.ac.jp.
Ken-Ichi AkagiNational Institute of Biomedical Innovation, Health and Nutrition 7-6-8 Saito Asagi Ibaraki-city Osaka 567-0085 Japan.
Muneki OouchiRIKEN Spring-8 Center 1-7-22 Suehiro-cho, Tsurumi-ku Yokohama 230-0045 Japan.
Fumiaki HayashiRIKEN Spring-8 Center 1-7-22 Suehiro-cho, Tsurumi-ku Yokohama 230-0045 Japan.
Takanori KigawaRIKEN Center for Biosystems Dynamics Research 1-7-22 Suehiro-cho, Tsurumi-ku Yokohama 230-0045 Japan.ORCID https://orcid.org/0000-0003-0146-9719
Midori Takimoto-KamimuraQuantum-Structural Life Science Laboratories, CBI Research Institute 3-11-1 Shibaura, Minato-ku Tokyo 108-0023 Japan kamimura@cbi-society.org.
Toshimichi FujiwaraInstitute for Protein Research, Osaka University 3-2 Yamadaoka Suita Osaka 565-0871 Japan.ORCID https://orcid.org/0000-0001-7739-3525
Chojiro KojimaInstitute for Protein Research, Osaka University 3-2 Yamadaoka Suita Osaka 565-0871 Japan.ORCID https://orcid.org/0000-0003-2723-8249

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fragment-based drug discovery (FBDD), which involves small compounds <300 Da, has been recognized as one of the most powerful tools for drug discovery. In FBDD, the affinity of hit compounds tends to be low, and the analysis of protein-compound interactions becomes difficult. In an effort to overcome such difficulty, we developed a

Identifiers

PMID36324497
PMCPMC9491350

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.